These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 20028267)
1. Re: Association between moxifloxacin ophthalmic solution and fungal infection in patients with corneal ulcers and microbial keratitis. Lane SS; Stroman DW; Cockrum P J Ocul Pharmacol Ther; 2009 Dec; 25(6):571; author reply 573-5. PubMed ID: 20028267 [No Abstract] [Full Text] [Related]
2. Association between moxifloxacin ophthalmic solution and fungal infection in patients with corneal ulcers and microbial keratitis. Mack RJ; Shott S; Schatz S; Farley SJ J Ocul Pharmacol Ther; 2009 Jun; 25(3):279-84. PubMed ID: 19348601 [TBL] [Abstract][Full Text] [Related]
3. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523 [TBL] [Abstract][Full Text] [Related]
4. Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases. Walter K; Tyler ME Cornea; 2006 Aug; 25(7):855-7. PubMed ID: 17068466 [TBL] [Abstract][Full Text] [Related]
5. The effects of moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3% treatment on corneal wound healing in pigmented rabbits following anterior keratectomy. Williams KK; McCartney MD; Rice RL; Wax MB; Hiddemen JW Vet Ophthalmol; 2008; 11(5):327-34. PubMed ID: 19046293 [TBL] [Abstract][Full Text] [Related]
6. Unorthodox ophthalmic preparations on the Ghanaian market: a potential risk for ocular and enteric infections. Kyei S; Dogbadze E; Tagoh S; Mwanza E Afr Health Sci; 2020 Mar; 20(1):515-523. PubMed ID: 33402940 [TBL] [Abstract][Full Text] [Related]
7. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Holland EJ; Lane SS; Kim T; Raizman M; Dunn S Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660 [TBL] [Abstract][Full Text] [Related]
8. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. Price MO; Price FW; Maclellan D J Cataract Refract Surg; 2005 Nov; 31(11):2137-41. PubMed ID: 16412928 [TBL] [Abstract][Full Text] [Related]
9. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Kim DH; Stark WJ; O'Brien TP; Dick JD Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125 [TBL] [Abstract][Full Text] [Related]
10. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. Yoshida J; Kim A; Pratzer KA; Stark WJ J Cataract Refract Surg; 2010 Sep; 36(9):1499-502. PubMed ID: 20692561 [TBL] [Abstract][Full Text] [Related]
11. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. McCulley JP; Caudle D; Aronowicz JD; Shine WE Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244 [TBL] [Abstract][Full Text] [Related]
12. Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients. Lindstrom R; Lane S; Cottingham A; Smith S; Sall K; Silverstein S; Shettle L; Walters T; Faulkner R; Cockrum P; Teuscher N J Ocul Pharmacol Ther; 2010 Dec; 26(6):591-5. PubMed ID: 20925517 [TBL] [Abstract][Full Text] [Related]